文献速递腹部MR

缩短肝脏MRI方案在结直肠癌肝转移患者随访中的临床表现

Clinical Performance of Abbreviated Liver MRI for the Follow-Up of Patients With Colorectal Liver Metastases.
PubMed 文献 · AJR Am J Roentgenol · 2021-01-27

本回顾性单中心研究纳入113例未接受化疗的结直肠癌肝转移患者,于化疗前及化疗后8-12周行钆塞酸二钠增强MRI,比较标准序列与缩短方案(肝胆期T1加权及DWI序列)在评估病灶存在、肝段受累及RECIST 1.1疗效反应方面的一致性。结果显示两种方案病灶总数高度一致(ICC=0.97),肝段受累加权κ=0.73-0.85,RECIST 1.1疗效分类加权κ=0.92,缩短方案可在不牺牲诊断性能的情况下减少成像时间。

要点

  • 缩短方案仅用肝胆期钆塞酸二钠增强T1加权及DWI序列,与标准方案病灶总数高度一致(ICC=0.97)。
  • 肝段受累评估两种方案一致性良好(加权κ=0.73-0.85),全肝段加权κ=0.82,差异未改变手术规划。
  • RECIST 1.1疗效分类两种方案一致性极好(加权κ=0.92),缩短方案可减少成像时间。

核心结论

  • 缩短肝脏MRI方案(肝胆期钆塞酸二钠增强T1加权及DWI序列)在化疗后评估中与标准肝脏MRI方案相似,可在不牺牲诊断性能的情况下减少成像时间。

研究设计与样本

  • 回顾性单中心研究,纳入2011年4月1日至2017年8月31日连续未接受化疗的结直肠癌肝转移患者113例(男73例、女40例,平均年龄61.6岁),在1.5-T设备上行钆塞酸二钠增强MRI,于化疗前及化疗后8-12周检查;两名放射科医生盲法独立阅片,参考标准为标准MRI序列。

诊断标准与关键数值

  • 病灶总数两种方案高度一致(组内相关系数=0.97);肝段受累一致性良好(加权κ=0.73-0.85),全肝段加权κ=0.82;RECIST 1.1疗效分类一致性极好(加权κ=0.92)。

临床应用与阅片要点

  • 作者结论认为缩短方案可用于化疗后评估,与标准方案相似,并能减少成像时间。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The objective of our study was to compare an abbreviated liver MRI protocol with a standard liver MRI protocol for the posttreatment follow-up of colorectal metastases in assessing disease presence, segmental involvement, and response to chemotherapy and for surgical planning. MATERIALS AND METHODS. This retrospective single-center study reviewed consecutive chemotherapy-naïve patients with colorectal liver metastases (April 1, 2011-August 31, 2017) who underwent gadoxetate disodium-enhanced MRI on a 1.5-T unit before and 8-12 weeks after chemotherapy. Two radiologists blinded to outcomes independently reviewed images obtained using standard MRI sequences at baseline and after treatment. The standard MRI sequences were the following: axial T1-weighted, axial T2-weighted, axial DWI (b values = 0-750 s/mm2), axial multiphase contrast-enhanced T1-weighted, and axial and coronal hepatobiliary phase (HBP) T1-weighted sequences. The standard sequences obtained at baseline and the abbreviated protocol sequences (i.e., HBP gadoxetate disodium-enhanced T1-weighted and DWI sequences) obtained after treatment were reviewed. For each image set, reviewers assessed disease presence and segmental involvement; in addition, for images obtained after therapy, treatment response according to RECIST 1.1 was recorded. RESULTS. One hundred thirteen patients (73 men and 40 women; mean age, 61.6 years) were evaluated. The total number of metastases showed high agreement between the standard protocol and abbreviated protocol (intraclass correlation coefficient = 0.97). There was good agreement between the protocols for segmental involvement (weighted κ = 0.73-0.85), and the weighted kappa was 0.82 for all segments. Discrepancies in segmental involvement did not alter potential surgical planning. Categorization of RECIST 1.1 treatment response using the abbreviated protocol versus the standard protocol showed excellent agreement (weighted κ = 0.92). CONCLUSION. An abbreviated liver MRI protocol (i.e., HBP gadoxetate disodium-enhanced T1-weighted and DWI sequences) allows assessment after chemotherapy similar to a standard liver MRI protocol. Use of the abbreviated protocol can reduce imaging time without sacrificing diagnostic performance for the follow-up of colorectal liver metastases.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Torkzad MR, Riddell AM, Chau I, et al. Clinical Performance of Abbreviated Liver MRI for the Follow-Up of Patients With Colorectal Liver Metastases. AJR Am J Roentgenol. 2021. PMID: 33502225. doi:10.2214/AJR.20.22854

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。